Abstract
AimTo evaluate the efficacy, safety, structural and functional progression following the insertion of iStent inject ® implants in patients with open-angle glaucoma or ocular hypertension at a tertiary-level hospital. Materials and methodsA retrospective study included 98 eyes (57 males and 41 females) with open-angle glaucoma or ocular hypertension, which underwent iStent inject W® implantation (Glaukos, Corporation, CA) between December 2018 and December 2022. Differences in intraocular pressure (IOP), the number of hypotensive eye drops used, and structural and functional tests were assessed between preoperative values and subsequent reviews during a follow-up period of one (n=98), two (n=55), and three years (n=15) after surgery. ResultsAmong the 98 eyes studied, 85% were diagnosed with open-angle glaucoma (50% mild, 32% moderate, and 18% severe) and 15% with ocular hypertension. There was a statistically significant reduction in IOP compared to preoperative values for all visits except the 1-month (p=0.36) and 3-year (p=0.39) visits. Visual acuity increased from 0.39±0.25 to 0.72±0.24 (p<0.01), considering that a significant portion of the interventions included cataract surgery. Before surgery, 66% of the sample used 2 or more hypotensive medications. Post-surgery, the number of hypotensive medications decreased (from 1.88±0.84 to 0.21±0.59 at 3 years) (p<0.01), with an 88.9% reduction in the number of medications over three years. After surgery, 75% of cases did not require any medication.Regarding structural and functional tests, thickness of retinal nerve fiber layers (RNFL (p=0.35), excavation / papilla ratio E/P (p=0.31), visual function index(VFI (p=0.06), and deviation mean (MD (p=0.06) showed no statistically significant differences post-intervention. However, standard deviation of the pattern (DSM) did exhibit differences, decreasing from 5.46±4.03dB to 5.34±3.48dB (p=0.02). ConclusionThe results of this study suggest that the iStent inject W® technique constitutes an effective and safe option for tension control and glaucoma treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
